Akero Therapeutics Inc
Change company Symbol lookup
Select an option...
AKRO Akero Therapeutics Inc
MRTX Mirati Therapeutics Inc
SIRC Solar Integrated Roofing Corp
CHSTY China High Speed Transmission Equipment Group Co Ltd
TTMZF Datable Technology Corp
WVFC W V S Financial Corp
WHLM Wilhelmina International Inc
SON Sonoco Products Co
VIRX Viracta Therapeutics Inc
PFS Provident Financial Services Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Akero Therapeutics Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is a hormone that protects against cellular stress and regulates the metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase IIb clinical trials in patients with biopsy-confirmed NASH: the study in pre-cirrhotic patients with F2-F3 fibrosis and the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Its EFX program is focused on patients with cirrhotic NASH (F4, compensated) in Phase IIb clinical trial.

Closing Price
$41.54
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Below Average)
Volume:
504,619

10-day average volume:
611,670
504,619

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

10:45 am ET October 3, 2022 (PR Newswire) Print

Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

https://mma.prnewswire.com/media/1486339/Pomerantz_Logo.jpg

The investigation concerns whether Kiromic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 2, 2021, Kiromic closed a public offering of 8 million shares of common stock priced at $5.00 per share, conducted pursuant to a registration statement filed with the U.S. Securities and Exchange Commission on June 25, 2021 (the "Offering"). On August 13, 2021, the Company issued a press release which made passing reference to "clinical hold issues" affecting the Company's Investigational New Drug applications for two immunotherapy products but did not otherwise expand on what those issues were. The press release stated, in relevant part, under the heading Events occurring after June 30, 2021 until August 13, 2021: "Communications with the FDA -- Supported by IQVIA, instead of simply addressing the FDA's questions with a written response only (WRO), we took the decision to apply for a Type A meeting with the FDA. The Type A meeting will address the clinical hold issues and will allow us to discuss path toward our first-in-human dosing."

Then, on November 18, 2021, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 in a timely manner. Finally, on January 27, 2022, Kiromic terminated Maurizio Chiriva-Internati as Chief Executive Officer for cause after finding evidence of "conduct that the Board believed was inconsistent with the Company's policies." The details of his conduct have not been publicly revealed. Since the Offering, Kiromic's common stock price has fallen more than 90%.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980

https://c212.net/c/img/favicon.png?sn=DC90267&sd=2022-10-03

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-kiromic-biopharma-inc--krbp-301638569.html

SOURCE Pomerantz LLP

https://rt.prnewswire.com/rt.gif?NewsItemId=DC90267&Transmission_Id=202210031045PR_NEWS_USPR_____DC90267&DateId=20221003

comtex tracking

COMTEX_415814186/1005/2022-10-03T10:45:04

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.